Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-277-1 | CAS number: 28874-51-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
The substance Sodium 5-oxo-L-prolinate is an organic substance, a white to pale yellow powder at ambient temperature; it has the molecular formula C5H7NO3.Na and a molecular weight of 151 g/mol. It is very soluble in water (613 g/L at 20 °C) and has a Log POW < 1.0. Sodium 5-oxo-L-prolinate is a substituted proline and is basic in nature, with a (Q)SAR estimated pKa value of 9.94.
As no specific studies on absorption, distribution, metabolism and excretion are available, the physico-chemical properties and the results of acute and repeat dose toxicity studies performed with Sodium 5-oxo-L-prolinate have been used to infer as far as possible, a toxicokinetic profile.
For risk assessment purposes, oral and inhalation absorption of Sodium 5-oxo-L-prolinate is assumed to be complete; dermal absorption is assumed at 1% as a worst-case estimate.
The substance will be widely distributed following absorption, and eventually utilised within the ‘γ-glutamyl cycle’ providing antioxidant for the body in the form of glutathione or for the synthesis of other amino acids.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 1
- Absorption rate - inhalation (%):
- 100
Additional information
Introduction
As no specific studies on absorption, distribution, metabolism and excretion are available, the physico-chemical properties and the results of acute and repeat dose toxicity studies have been used to determine, as far as possible, a toxicokinetic profile for Sodium 5-oxo-L-prolinate.
Physicochemical properties
The substance Sodium 5-oxo-L-prolinate is an organic substance, a white to pale yellow powder at ambient temperature; it has the molecular formula C5H7NO3.Na and a molecular weight of 151 g/mol. It is moderately soluble in water (613 g/L at 20 °C) and has a Log POW of < 1.0. The vapour pressure is 0.54 kPa at 20 °C.
Sodium 5-oxo-L-prolinate is the sodium salt of an uncommon amino acid derivative in which the free amino group of glutamic acid or glutamine cyclises to form a lactam and is basic in nature, with a (Q)SAR estimated pKa value of 9.94.
Absorption
Oral absorption
The small molecular weight, together with the moderate water solubility and moderate Log POW all suggest readily absorption following oral administration, mainly through the intestinal tract where the pH is a little more basic.
In a published paper (Ishii et al., 1992), the substance was administered via the diet at extremely high dosages (up to 7000-8000 mg/kg bw/day) to rats for either 13 or 26 weeks; in addition to the control group (untreated diet), the study included a concurrent control receiving sodium at a level corresponding to that contained at the highest dose level. Treatment was well tolerated, without any signs of over toxicity or mortality. Changes included observation of soft faeces, up to week 9 of treatment, considered related to a transient insufficient adaptation of the intestinal tract due to the intake of food which contains large amount of highly-moisturizing test substance, increased water consumption, slight increase in urine pH value, and organ weight as well as microscopic changes in kidneys, which were comparable to the Na-treated controls and considered adaptive to the constant high load of sodium.
The ‘soft faces’, observed till week 9 of treatment, and the similarity of results obtained for the high dose animals and the Na-treated controls confirm that the substance was completely absorbed, and that it does not accumulate and possesses a highly favourable toxicological profile.
In addition, in a fully compliant recently performed OECD 421 study (Kiss, 2013), no adverse effects were noted for any of the parameters evaluated and the NOAEL/NOEL for parental, reproductive and developmental toxicity was the limit dose of 1000 mg/kg bw/day.
For risk assessment purposes, oral absorption is assumed to be complete.
Dermal absorption
The substance is reported to be a normal constituent of the stratum corneum, as one of the hygroscopic components of the water-soluble fraction that helps to maintain the moisture content of the corneum (Laden and Spotzes, 1967).
Nothing can be inferred from the acute dermal toxicity study, because, as in the case of oral administration, the LD50 was greater than the limit dose of 2000 mg/kg bw and no signs of local or systemic toxicity were noted.
The Log POW, lower than 1, also supports limited penetration into the stratum corneum, and hence dermal absorption.
For risk assessment purposes, dermal absorption is assumed at 1%, as a really worst-case estimate.
Inhalation absorption
The substance has a vapour pressure of 0.54 kPa at 20 °C and is marketed as a solution therefore inhalation exposure is not expected to occur. However, the moderate water solubility, low Log POW, and the likely complete absorption following oral administration, suggest that the substance can readily absorbed if inhaled.
In the absence of quantitative data, complete absorption following inhalation is assumed for risk assessment purposes.
Distribution
The small molecular weight (even smaller when the salt dissolves) and moderate water solubility suggest that the substance would be widely distributed within the body.
Metabolism
As indicated by the drinking behaviour of rats dosed at extremely high doses for up to 3 months, and adaptive changes in the kidney, sodium released from the salt is absorbed from the intestine and enters into the large physiological pool for this electrolyte existing within the body.
5-oxo-L-proline is the substrate of the enzyme 5-oxoprolinase that catalyzes the conversion of 5-oxoproline to glutamate in the presence of ATP, and is present mainly in the kidney but was also found in rat liver, spleen, lung, and brain (Van Der Werf et al., 1971).
Elimination
Sodium will be eventually excreted in the urine. 5-oxo-L-proline will be not excreted, but converted into glutamate and then utilised within the ‘γ-glutamyl cycle’ providing antioxidant for the body in the form of glutathione or for the synthesis of other amino acids.
Conclusion
For risk assessment purposes, oral and inhalation absorption of Sodium 5-oxo-L-prolinate is assumed to be complete; dermal absorption is assumed at 1% as a worst-case estimate.
References
Ishii H., Fujimoto T., Ninomiya K. & Torii K. (1992)
Toxicity Study of Sodium L-2-Pyrrolidone-5-carboxylate (PCA-Na) Administered to Rats in Diet for 13 and 26 Weeks
IYAKUHIN KENKYU, 23 (6), 717-736
Laden K. & Spotzes R. (1967)
Identification of a natural moisturizing agent in skin
J. Soc. Cosmet. Chem., 18, 351
Van Der Werf P., Orlowski M. & Meister A. (1971)
Proc. Nat. Acad. Sci. USA, 68 (12), 2982-2985
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.